(PHG) Koninklijke Philips - Ratings and Ratios
Exchange: NYSE • Country: Netherlands • Currency: USD • Type: Common Stock • ISIN: US5004723038
PHG: Medical, Imaging, Diagnostic, Treatment, Care, Health
Koninklijke Philips N.V. stands as a titan in the health technology sector, strategically positioned to capitalize on the accelerating convergence of healthcare and technology. Operating across North America, Greater China, and international markets, Philips is organized into three core segments: Diagnosis & Treatment, Connected Care, and Personal Health. This structure allows the company to address the full continuum of healthcare needs, from diagnosis to treatment and ongoing care.
In the Diagnosis & Treatment division, Philips excels in advanced medical imaging, offering MRI, X-ray, and CT systems. Their cutting-edge detector-based spectral CT solutions provide unparalleled imaging clarity, while molecular and hybrid imaging solutions advance nuclear medicine. Echography solutions are tailored for cardiology, general imaging, obstetrics/gynecology, and point-of-care, enhancing both diagnosis and treatment planning. Additionally, Philips interventional systems and devices treat coronary artery and peripheral vascular diseases, underscoring their commitment to innovative, minimally invasive therapies.
The Connected Care segment delivers integrated solutions that are pivotal in todays healthcare landscape. Philips offers acute patient management systems, emergency care solutions, and sleep and respiratory care technologies. Their electronic medical record and care management solutions facilitate seamless data integration, crucial for modern healthcares shift towards preventive and personalized medicine.
Personal Health focuses on consumer-centric products that enhance daily health routines. Philips provides power toothbrushes, interdental cleaning solutions, and teeth whitening products, alongside infant feeding solutions, baby monitors, and grooming products. These offerings not only drive recurring revenue but also build brand loyalty, reflecting Philips strategy to integrate health technology into everyday life.
Philips strategic partnerships with leading healthcare providers like TriHealth, Northwell, and Mayo Clinic highlight their collaborative approach and market validation. These partnerships underscore their commitment to innovation and integration, crucial in the evolving healthcare ecosystem.
Originally founded in 1891 as a broad electronics company, Philips transformed into a focused health tech leader, renaming to Koninklijke Philips N.V. in 2013. This evolution reflects their strategic pivot towards healthcare, aligning with global trends towards preventive and integrated care.
Financially, Philips boasts a market cap of $25.384 billion, with a forward P/E of 15.55, indicating investor confidence in future growth. Their price-to-book ratio of 2.07 and price-to-sales ratio of 1.42 highlight their valuation metrics, providing insight into their market position and stability.
In summary, Kon
Additional Sources for PHG Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PHG Stock Overview
Market Cap in USD | 25,385m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 1987-12-30 |
PHG Stock Ratings
Growth 5y | -11.5% |
Fundamental | -11.1% |
Dividend | 15.2% |
Rel. Strength Industry | 29.2 |
Analysts | 4/5 |
Fair Price Momentum | 26.33 USD |
Fair Price DCF | 28.39 USD |
PHG Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | -100.00% |
Payout Consistency | 71.5% |
PHG Growth Ratios
Growth Correlation 3m | 54.9% |
Growth Correlation 12m | 30.3% |
Growth Correlation 5y | -58.9% |
CAGR 5y | 0.13% |
CAGR/Max DD 5y | 0.00 |
Sharpe Ratio 12m | 0.23 |
Alpha | 22.60 |
Beta | 0.43 |
Volatility | 39.32% |
Current Volume | 608.4k |
Average Volume 20d | 832.2k |
As of March 13, 2025, the stock is trading at USD 26.65 with a total of 608,416 shares traded.
Over the past week, the price has changed by -1.81%, over one month by -5.46%, over three months by +3.98% and over the past year by +29.09%.
Neither. Based on ValueRay Fundamental Analyses, Koninklijke Philips is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -11.08 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PHG as of March 2025 is 26.33. This means that PHG is currently overvalued and has a potential downside of -1.2%.
Koninklijke Philips has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy PHG.
- Strong Buy: 1
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, PHG Koninklijke Philips will be worth about 28.4 in March 2026. The stock is currently trading at 26.65. This means that the stock has a potential upside of +6.72%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 34.5 | 29.5% |
Analysts Target Price | 34.5 | 29.5% |
ValueRay Target Price | 28.4 | 6.7% |